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Mesenchymal stem/stromal cells (MSCs) represent a promising cell source for research and therapeutic applications, but their
restricted ex vivo propagation capabilities limit putative applications. Substantial self-renewing of stem cells can be achieved
by reprogramming cells into induced pluripotent stem cells (iPSCs) that can be easily expanded as undifferentiated cells even
in mass culture. Here, we investigated a differentiation protocol enabling the generation and selection of human iPSC-derived
MSCs exhibiting relevant surface marker expression profiles (CD105 and CD73) and functional characteristics. We generated such
iPSC-MSCs from fibroblasts and bone marrow MSCs utilizing two different reprogramming constructs. All such iPSC-MSCs
exhibited the characteristics of normal bone marrow-derived (BM) MSCs. In direct comparison to BM-MSCs our iPSC-MSCs
exhibited a similar surface marker expression profile but shorter doubling times without reaching senescence within 20 passages.
Considering functional capabilities, iPSC-MSCs provided supportive feeder layer for CD34+ hematopoietic stem cells’ self-renewal
and colony forming capacities. Furthermore, iPSC-MSCs gained immunomodulatory function to suppress CD4+ cell proliferation,
reduce proinflammatory cytokines in mixed lymphocyte reaction, and increase regulatory CD4+/CD69+/CD25+ T-lymphocyte
population. In conclusion, we generated fully functional MSCs from various iPSC lines irrespective of their starting cell source or
reprogramming factor composition andwe suggest that such iPSC-MSCs allow repetitive cell applications for advanced therapeutic
approaches.
1. Introduction
Regarding clinical stem cell applications, mesenchymal stem/
stromal cells (MSCs) have been introduced as a favorable cell
type, which can be maintained ex vivo and have the potential
to regenerate mesodermal tissues such as cartilage, tendon,
bone, and muscle in variety of skeletal diseases (for review
see [1]). Furthermore,MSCs can support hematopoiesis [2, 3]
and are able to modulate inflammatory reactions by dynamic
interplay with the innate and adaptive immune systems [4–
6]. However, the limited proliferation capability of MSCs
during long-term culture leading to cellular senescence after
8–10 passages challenges the generation of large-scale cell
yields, which would be essential for repetitive therapeutic
applications. In principal, such needs would be met by
pluripotent stem cells exhibiting an unlimited proliferation
capacity and that can be generated from patients’ samples
via reprogramming of somatic cells into induced pluripotent
stem cells (iPSCs) [7–10]. Such human iPSCs are responsive
to differentiation stimuli during in vitro cultivation and
in the recent past the generation of iPSC-derived MSCs
(iPSC-MSCs) was described and it was demonstrated that
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iPSC-MSCs displayed comparable antigen profile and dif-
ferentiation capability to bone marrow MSCs (BM-MSCs)
and exhibited considerable functional properties [11–16].
Moreover, there is convincing evidence that iPSC-MSCs with
higher expansion capacities can be transplanted in many
degenerative diseases resulting in similar outcomes as BM-
MSCs [13, 15, 17]. Increasing evidence, however, indicates
that MSCs from different origins are heterogeneous popu-
lations exhibiting variable gene expression patterns [18, 19],
presenting different surfacemarkers [20], or showing reduced
proliferation potential and differentiation capacities [21–23].
Furthermore, a successful approach of iPSC-based ther-
apeutic cell applications in regenerative medicine depends
on the ability to set up an efficient differentiation protocol
resulting in a desired cell population with a high purity.
Most importantly, harmful contaminations of undifferenti-
ated pluripotent stem cells must be avoided, to exclude the
risk of teratoma formation. Therefore, the robust genera-
tion of a homogenous iPSC-MSC population with cellular
characteristics identical to bona fide MSCs and similar or
even enhanced functional capabilities such as proliferation,
hematopoietic support, and anti-inflammatory responses
need further attention. Here, we exploited the differentiation
potential of three iPSC lines generated from fibroblast or
primary MSCs with Yamanaka reprogramming factors [10],
namely, Oct4, Sox2, Klf4, and c-Myc (OSKM) or Thomson
factors [7], namely, Oct4, Sox2, Nanog, and Lin28 (OSNL).
Upon MSC differentiation we applied lentiviral selection
constructs carrying CD105- and CD73-promoter driven
fluorescent reporter and Neomycin/Puromycin-resistance-
transgenes to enrich the bulk differentiation for fully differ-
entiated MSCs. Next, we explored the antigen profile, dif-
ferentiation potential, proliferation capacity, hematopoietic
support, and immune-suppression potential in regulation of
lymphocyte proliferation, proinflammatory cytokine secre-
tions, and activation markers of such iPSC-MSCs in direct
comparison to bone marrow MSCs (BM-MSCs) from three
different donors (LM02, LM05, and LM06).
2. Material and Methods
2.1. Human iPS Cell Culture. Human fetal liver fibroblast
(FLF) iPS cells were provided from in-house supplies using
transduction via lentiviral reprogramming factors Oct4,
Sox2, Klf4, and c-Myc (OSKM) [24] and Oct4, Sox2, Nanog,
and Lin28 (OSNL) [25]. Human iPSCs were cultured on
irradiated mouse embryonic fibroblasts (MEF) in a humid-
ified incubator at 37∘C and 5% CO
2
in medium contain-
ing DMEM/F-12, 20% knockout serum replacement (Life
Technologies), 20 ng/mL human recombinant basic fibrob-
last growth factor (bFGF, provided from Leibniz University
Hannover), 0.1mM 𝛽-mercaptoethanol (Life Technologies),
1mM L-glutamine, 1% nonessential amino acids, and 1%
penicillin/streptomycin (all from Sigma-Aldrich).
Media were changed daily and cells were split weekly by
dissociation with 200U/mL of collagenase IV (Life Tech-
nologies) and cells were plated on Matrigel-coated plates
in medium supplemented with 40 ng/mL bFGF for further
differentiation.
2.2. Derivation and Enrichment of Human MSC-Like Cells.
For triggering iPSC differentiation toward MSC-like cells,
human iPSC colonies grown on Matrigel (Corning) were
maintained with MSC induction media consisting of DMEM
(low-glucose, Sigma-Aldrich), 10% defined fetal bovine
serum (FBS, STEMCELL Technologies), 1% nonessen-
tial amino acids, 1% penicillin-streptomycin, and 2 ng/mL
human recombinant bFGF for 7 days. Next, cells were treated
with collagenase IV for 3min at 37∘C, dissociated by glass
beads and gentle pipetting, and then passed through 40 mm
cell strainers (Fisher Scientific). Single cells were seeded onto
gelatin-coated plates at 1 × 104 cells/cm2 in MSC media.
To facilitate enrichment and screening of MSCs during
the standard differentiation protocol of iPSCs into MSCs,
a combination of two positive markers, namely, CD73 and
CD105 (which are consistently expressed in MSCs), was cho-
sen to produce MSC-specific selection vectors.The promoter
regions for CD73 and CD105 were amplified and ligated into
the corresponding lentiviral backbone; the CD105 promoter
into pRRL-Puro-IRES-GFP; and the CD73 promoter into
pRRL-neo-IRES-dTom. (Lentiviral backbones provided in-
house based on lentiviral constructs from Axel Scham-
bach laboratory). Cells were selected by 500 𝜇g/mL G-418
and 4 𝜇g/mL Puromycin-dihydrochloride (both from Sigma-
Aldrich) in culture media for 2 weeks until the untransfected
cells were killed. Functionality of the vectors confirmed
fluorochrome expression in transduced cells by fluorescent
microscope afterwards.
Double-positive MSCs population transduced with
pRRL-CD105-Puro-IRES-GFP and pRRLCD73-neo-IRES-
dTom was purified with the FACSAria II cell sorter (BD
Bioscience). A total of 2 × 106 sorted cells were immediately
plated back into gelatin-coated plates to facilitate adherence.
After 24 hours, fresh prewarmed MSCs medium was added
and cells were allowed to expand and reach nearly 100%
confluence. Cells were counted in different time points.
Bone marrow MSCs were isolated in Frankfurt university
hospital as previously described [26]. Shortly 10–30mL of
bone marrow was aspirated from femoral cavity of patients
who needed hip joint replacement surgery after informed
consent in accordance with the Declaration of Helsinki. After
density gradient separation, the light density mononuclear
cell fraction was seeded on T25 (TPP) tissue culture flasks in
previously mentioned MSC media.
2.3. Lentiviral Vectors Production. HEK 293T cells were used
for virus production. 3 × 106 cells were seeded one day
before transfection in 10 cm dishes (TPP) in DMEM (high
glucose, Life Technologies) supplemented with 10% FBS and
1%penicillin/streptomycin and 1%L-glutamine.Thenext day,
medium was exchanged with 8mL DMEM supplemented
with 25 𝜇M Chloroquine (Sigma-Aldrich). Plasmids encod-
ing for lentiviral gag/pol (pCDNA3.GP.CCCC, 10 𝜇g), RSV-
Rev (pRSV-Rev, 5𝜇g), VSV-G (pMD2.G, 2𝜇g), and packag-
ing plasmid encoding for respective transgene into pRRL-
Puro-IRES-GFP and pRRL-neo-IRES-dTom were mixed in
400 𝜇L of ddH
2





mixture was added dropwise to 2xHBS and observed
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until precipitates became visible in phase-contrast micro-
scope and then added toHEKcells. 6 hours later,mediumwas
exchanged with 10mL DMEM high glucose supplemented
with 10% FBS and 1% penicillin/streptomycin and 1% L-
glutamine. 48 hours later, supernatant was collected, passed
through 0.45 𝜇m filters, and centrifuged at 14,000×g for
8 h. Virus pellet was resuspended in 200𝜇L PBS (Sigma-
Aldrich). Viral titers were determined by transduction of
HEK 293T cells in serial dilutions and analysis of reporter
gene expression by flow cytometry. Generally, titers were in
the range of 1-2 × 107 viral particles per mL.
2.4. Antigen Profiling by Flow Cytometry. To assess the im-
munophenotypic profile of BM-MSCs and iPSC-derived
MSCs, single cell suspensions were prepared by trypsin
digestion (Life Technologies) and washed with cold PBS
containing 1% bovine serum albumin BSA (MerckMillipore).
Next, 2 × 105 cells were incubated for 30 minutes with the
respective APC-conjugated monoclonal antibodies: CD73,
CD90, CD105, CD45, CD34, and CD19 (all from BD Bio-
science listed in Table 1), and subsequently resuspended in
a density of 2 × 105 cells per 200𝜇L in cold PBS contain-
ing 1% BSA. Nonspecific fluorescence was determined by
incubation of cell aliquots with isotype-matched monoclonal
antibodies.
Samples were run on a FACS Calibur (BD Bioscience)
cytometer using FACS Diva software. For each analysis, a
minimum of 10,000 cells was assayed. Data was further
processed using FlowJo Software (Tree Star).
2.5. Growth Kinetics. Human BMSCs from 3 different donors
(LM02, LM05, and LM06) and 3 iPSC-MSCs lineswere plated
(2 × 104 cells/well) onto 12-well plates in triplicate. Cells
were harvested after 72 hours in each passage (10 passages
for BM-MSCs and 15 passages for iPSC-MSCs). Cumulative
population doublings were calculated using the formula: 𝑥 =
[log 10(NH) − log 10(𝑁1)]/ log 10(2) [27], where 𝑁1 is the
inoculum cell number and NH the cell harvest number. To
yield the cumulated doubling level, the population doubling
for each passage was calculated and then added to the
population doubling levels of the previous passages. The
cultures were abandoned as soon as they showed a senescent
phenotype when they ceased proliferation.
2.6. In Vitro Adipogenic, Chondrogenic, and Osteogenic Dif-
ferentiation. Differentiation induction of iPSC-MSCs was
carried out for 21 days in different differentiation media.
Totally 104 cells were seeded per well in six-well plates
(TPP). To induce osteogenic differentiation, cells were cul-
tured with MSC medium containing 1 𝜇M dexamethasone,
0.5 𝜇M ascorbic acid, and 10mM b-glycerol phosphate (all
from Sigma-Aldrich). For adipogenic induction, cells were
cultured in MSC medium supplemented with 50 𝜇g/mL
indomethacin (Sigma-Aldrich), 50𝜇g/mL ascorbic acid, and
100 nM dexamethasone. For chondrogenic differentiation,
iPSC-MSCs were centrifuged in 0.2mL of medium at
500 g for 10min in 15 mL Falcon tubes to form a pellet.
The pellets were cultured in MSC medium supplemented
Table 1: List of antibodies and ELISA kits used in this study.
Antibody/ELISA kit Company Dilution Cat. number
CD-45 BD Bioscience 1 : 100 555485
CD-105 BD Bioscience 1 : 100 562408
CD-34 BD Bioscience 1 : 100 555824
CD-73 BD Bioscience 1 : 100 560847
CD-19 BD Bioscience 1 : 100 555419
CD-90 BD Bioscience 1 : 100 555595
CD-25 BD Bioscience 1 : 100 555431
CD-69 BD Bioscience 1 : 100 555530
CD-4 BD Bioscience 1 : 100 340419
CD-11b BD Bioscience 1 : 100 557321
CD-14 BD Bioscience 1 : 100 557742
SSEA-4 BD Bioscience 1 : 100 560128
OCT-4 Santa Cruz 1 : 200 SC-5279
SOX-2 Santa Cruz 1 : 200 SC-17320
Human IFN-𝛾 BD Bioscience — 550612
Human IL-2 BD Bioscience — 550611
with 0.01𝜇M dexamethasone, 397 𝜇g/mL ascorbic acid-2-
phosphate (Sigma-Aldrich), 1mM sodium pyruvate (Sigma-
Aldrich), 10 ng/mL transforming growth factor-𝛽1 (TGF-𝛽1,
Life Technologies), and 1% insulin-transferrin-selenium (Life
Technologies). Osteogenesis was assessed by alizarin red
staining, adipogenesis by oil red staining, and chondrogen-
esis by alcian blue staining (all from Sigma-Aldrich).
2.7. Real Time qRT PCR. Total cellular RNA was isolated
using TRIzol reagent (Life Technologies). Resultant RNA
was subjected to DNase treatment and cDNA Synthesis Kit
(Life Technologies) with random hexamers. Power SYBR
Green Master Mix based qRT PCR assays were performed
on the StepOne Plus Cycler (Applied Biosystems) using the
standard settings. We collected samples from at least three
independent experiments. Expression values of human per-
oxisome proliferator-activated receptor 𝛾 (PPAR𝛾), PPAR𝛼,
lipoprotein lipase (LPL), collagen type II (COL2), aggre-
can (ACAN), osteocalcin (OCN), and alkaline phosphatase
(ALP) normalized to expression of GAPDH. The primer
sequences are listed in Table 2.
2.8. Coculture of CD34+ Progenitor Cells with iPSC-MSCs.
Human iPSC-MSCs or BM-MSCs layers were grown until
80% confluency in six-well plates and then treated with
mitomycine-C (Sigma-Aldrich) to prevent cell overgrowth.
After 24 h, medium was removed and purified CD34+
cells (resuspended at 7.5 × 104 cells per well) were then
added in 2mL of long-term culture medium containing 𝛼-
minimal essentialmedium (Life Technologies) with 20%FBS,
1 𝜇mol/L hydrocortisone (Sigma-Aldrich), and 0.1mM 𝛽-
mercaptoethanol. The cocultures were incubated for 20 days
medium exchange twice per week. Nonadherent viable cells
were counted at the indicated time points (day 10 and day
20). CD-markers for hematopoietic differentiation were also
determined after 8 days for CD34, CD45, CD-11b, and CD-14.
Experiments were repeated three times.
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Table 2: List of primers used in this study qRT-PCR.
Gene symbol Sequences 5󸀠-3󸀠, forward Sequences 5󸀠-3󸀠, reverse Size (bp) Annealingtemp. (∘C)
Accession
number
PPAR𝛾 CTAAAGAGCCTGCGAAAG TGTCTGTCTCCGTCTTCTTG 331 60 NM 015869.4
PPAR𝛼 ACTCCGTCTTCTTGATGAT TGCTATCATTTGCTGTGGAG 215 60 NM 005036.4
LPL TCAACTGGATGGAGGAG GGGGCTTCTGCATACTCAAA 169 60 NM 000237.2
COL2a TCTACCCCAATCCAGCAAAC GCGTAGGAAGGTCATCTGGA 170 60 NM 033150.2
ACAN CTGGACAAGTGCTATGCCG GAAGGAACCGCTGAAATGC 191 60 NM 013227.3
BGLAP (OCN) GGCAGCGAGGTAGTGAAGAG CAGCAGAGCGACACCCTAGAC 195 60 NM 199173
ALP CAACAGGGTAGATTTCTCTTGG GGTCAGATCCAGAATGTTCC 136 60 NM 000478.4
GAPDH CTCATTTCCTGGTATGACAACGA CTTCCTCTTGTGCTCTTGCT 122 60 NM 002046.3
2.9. In Vitro Progenitor Assays. Effects of human iPSC-MSCs
or BM-MSCs on progenitor cells were analyzed using a
colony forming cell assay. Human bone marrow CD34+ cells
(2 × 106) were obtained from Lonza and were plated in 2mL
of methylcellulose media (STEMCELL Technologies) with or
without iPSC-MSCs and BMSCs. Colonies of >50 cells were
scored after 4 and 8 days of incubation.
2.10. Assessment of CD4+ T-Lymphocyte ProliferationResponse
to iPSC-MSCs. Standard 5-day MLR cultures were set up
with 5 × 104 Mitomycin C–treated (Sigma-Aldrich) human
peripheral blood mononuclear cells (PBMCs) as stimula-
tors and 2 × 105 human CD4+ T-cells (Lonza) in 96-well
round-bottom plates in 200𝜇L complete medium consisting
RPMI 1640 (Life Technologies) supplemented with 0.1mM
𝛽-mercaptoethanol, 10% FBS, GLUTAMAX I (Life Tech-
nologies), 100U/mL penicillin, and 100 𝜇g/mL streptomycin
in the presence or absence of iPSC-MSCs and BM-MSCs.
For analyzing expression of CD69+ and CD25+ regulatory
T-cell population, 106 responder cells were mixed with 2.5
× 105 stimulator PMNCs in presence or absence of 2 ×
105 iPSC-MSCs or BM-MSCs. MLRs were performed on
a layer of confluent Mitomycine C treated MSCs seeded
one day before. Proliferation was determined with BrdU
ELISA assay (Roche) based on manufacturer instruction. IL-
2 and IFN-𝛾 concentration was determined in MSC/MLR
coculture supernatants using a commercially available ELISA
(BD Bioscience) according to manufacturer’s instructions.
CD25 and CD69 (BD Bioscience) expression on CD4+ cells
were analyzed by flow cytometry.
3. Results and Discussion
3.1. Generation of MSCs from Human iPSCs with Spindle-
Shape Morphology. The challenge of accessing an appro-
priate and homogenous source for MSCs with sustained
growth kinetics, immunosuppressive potentials, and produc-
tion of chemokines or growth factors supporting endogenous
regeneration led to the question whether homogenously
differentiated MSCs could be derived from human induced
pluripotent stem cells (iPSCs). To address this question, we
used two different sources of somatic cells, liver fibroblast
and bone marrow-derived MSCs (BM-MSCs), and repro-
grammed these cells into iPSCs. Besides two sources of
somatic starting cells, we also compared two slightly dif-
ferent composition of reprograming factor cocktails. One
factor combination was comprised of Oct4, Sox2, Klf4, and
c-Myc (OSKM) as it was originally described by Shinya
Yamanaka and subsequently in multitudinous publications
[8–10] and the other combination consisted of Oct4, Sox2,
Nanog, and Lin28 (OSNL) as it was described by James
Thomson and some further groups [7, 25]. Taken together, we
generated fetal liver fibroblast-derived iPSCswithOSKMand
OSNL (FLF iPSCs) and bone marrow MSC-derived iPSCs
with OSKM (MSC-iPSCs), which were strongly expressing
OCT4, SOX2, and SSEA-4 (Figure 1). All iPSC lines were
differentiated based on a previously reported differentiation
protocol resulting in about 70% CD73+/CD105+ cells [14],
in which we have made some modifications to allow for
antibiotic selection and fluorescent reporter-based purifi-
cation (Figure 2(a)). As expected, Epithelial-Mesenchymal
Transition occurred during differentiation giving rise to
a heterogeneous population (Figure 2(b)). However, with
enrichment of early mesenchymal-like cells, we observed
intermediate and highly CD73-dTom/CD105-GFP express-
ing cells populations (Figure 2(c)). We sorted highly express-
ing GFP/dTom positive cells and obtained a much more
homogenous population (Figure 2(d)). Stimulated by the first
description of iPSC-derived MSCs by Lian et al. in 2010
[15], many other groups tried to do direct and spontaneously
differentiating iPSCs into MSCs by various means. We con-
sider the use of lentiviral reporter and selection constructs
as important tools to monitor the purity of a cell population
during differentiation processes and to ensure a high grade of
homogeneity within the final cell population. Such selection
constructs were recently introduced in other lineages’ differ-
entiation protocols [28]. Thus, in the present study a similar
vector architecture was applied to select for CD73+/CD105+
positive iPSC-MSCs. Interestingly, we obtained a high num-
ber of CD73pos/CD105intermediate iPSC-MSCs (R1: 63.3%)
and a smaller fraction of CD73pos/CD105high iPSC-MSCs
(R2: 6.43%) and we concluded that sorting the less abun-
dant CD73pos/CD105high population might provide the most
homogenous cell population.
3.2. Immunophenotype, Proliferation, and Differentiation Po-
tential of iPSC-MSCs. In order to characterize the iPSC-
MSCs according to the International Society of Cell Therapy


































































Figure 1: Generation and characterization iPS cells from human fetal liver fibroblasts (FLF) with Oct4, Sox2, Klf4, and c-Myc (OSKM) and
Oct4, Sox2, Nanog, and Lin-28 (OSNL) and also from human bonemarrowMSCs with OSKMusing lentiviral vectors. iPSCs stained positive
for humanOCT4 and SOX2.DAPIwas used to stain the nuclei andmergedwith phase-contrast. Expression of SSEA-4 is shown in histograms.
(ISCT) criteria [29] cell surface marker expression was ana-
lyzed by flow cytometry of all three iPSC-MSC lines and BM-
MSCs at early passages (passages 3–6). All 3 differentiated and
enriched iPSC-MSCs displayed a MSC-like antigen profile
that exhibited high CD105, CD73, and CD90 and absence
of CD34, CD45, and CD19 expression (Figure 3(a)). Thus,
we were able to demonstrate that homogenous populations
can be isolated and purified from all three iPSC lines
independent to their somatic cell source (fibroblasts or bone
marrow MSCs) and method of reprogramming (OSKM or
OSNL factor cocktail). Strikingly, the surface marker CD105
and CD73, whose promoter motifs were utilized to express
the fluorescent reporter transgenes and antibiotic selection
cassettes, were readily detectable in almost 100% of purified
cells, indicating the high purity of our enriched iPSC-MSCs.
Interestingly, CD90 was positive not only in all iPSC-MSCs
lines as well as the BM-MSCs but also in undifferenti-
ated iPSCs (MSC-iPSCs). Furthermore, the hematopoietic
surface markers were neither expressed in MSCs nor in
iPSCs.
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Figure 2: Derivation and enrichment of MSCs from human iPS cells. (a) Schematic stepwise protocol for differentiation and selection of
MSC-like cells from human iPS cells. (b) phase-contrast photos demonstrating Epithelial-Mesenchymal transition in cellular morphology.
(c) FACS dot blot showing intermediate (R1) and highly (P2) double-positive cells. Highly positive CD-73 and CD-105 (R2) were sorted for
upcoming experiments. (d) iPS-MSCs after sorting showed more homogenous mesenchymal morphology expressing GFP/dTom.
Growth kinetics of iPSC-MSCs demonstrated a greater
proliferative capacity when compared with BM-MSCs with
shorter doubling times (Figure 3(b)). In our experiments,
three independently derived BM-MSCs exhibited doubling
times around 36 h in early passages that were prolonged
above 60 h around passage 8 and followed by a cessation of
proliferation with an apparent senescent phenotype around
passage 10 (Figure 3(b)). In contrast, all three iPSC-MSCs
exhibited significantly shorter doubling times (around 20 h
in early passages). The prolonged doubling time of more
than 60 h did not occur before passage 15 and even after 20
passages iPSC-MSCs did not show a senescent phenotype.
These results are in line with previously reported data from
Sánchez et al., who showed that human embryonic stem cell-
derived CD73+ and CD90+ MSCs had higher proliferation
rate than BM-MSCs (ESCs-MSCs∼18 doubling compared to
BM-MSCs∼5 doubling in 30 days of culture) but were similar
to umbilical cord derived MSCs (∼15 doubling in 30 days)
[12]. The more robust proliferation potential of iPSC-MSCs
suggests an important advantage over BM-MSCs, whenever
repetitive transplantations of the very sameMSCbatchwould
be most preferential (for review of this impact on age-related
disorders, see [30]). Although the dosing of MSCs perfusion
is currently controversially discussed for different disor-
ders, one can assume that an increasing demand of MSCs
transplantation may arise in certain disorders. For example,
musculoskeletal injuries with high occurrence in seniors [31]
may urge for engineered MSCs with higher proliferation
capabilities but same functional abilities as BM-MSCs. Thus,
iPSC-MSCs may serve as “off the shelf transplant,” which
can be provided by blood/stem cell banking institutions and
used for several degenerative diseases. Moreover, the higher
homogeneity of such well-proliferating, nonsenescent iPSC-
MSCs populations suggest a higher safety and efficacy profile
















































































































































































































































































































































































































































































































































































Figure 3: Antigen phenotype, proliferation rate, and functional characterization of hiPSC-MSCs. (a) Immunophenotype of the three hiPS-
MSCs lines generated. Representative flow cytometry analysis of hBM-MSCs, FLF-iPSC-MSCs (OSKM), FLF-iPSC-MSCs (OSNL), MSC-
iPSC-MSCs (OSKM), and MSC-derived iPSC line MSC-related markers CD73, CD90, and CD105 and hematopoietic CD45, CD34, and
CD19 were assessed (solid histogram). (b) In vitro cell growth, measured as cumulative population of hiPSC-MSCs and BM-MSCs derived
from 3 different donors (LM02, LM05, and LM06).
andmay qualify such cells formore long-term treatment such
as inflammatory bowel diseases or during the prevention of
graft versus host diseases or transplant rejection in future
transplantation settings [12].
Addressing the functional capabilities of iPSC-derived
MSCs we applied differentiation protocols towards adipo-,
osteo-, or chondrogenic lineages, respectively, and performed
cytological staining andRT-PCR to investigate changes in cell
morphological and related marker gene expression. Impor-
tantly, all 3 iPSC-MSCs could give rise to all of these three
lineages. However, in comparison to BM-MSCs the quality
and morphology characteristics of the differentiated iPSC-
MSCs exhibited slight differences. All iPSC-MSCs were more
reluctant to adipogenic differentiation and the respective total
numbers of differentiated cells containing lipid droplets were
lower than that of BM-MSCs (Figure 4). This observation
was confirmed with adipocytes specific mRNA level in which
expression levels of PPAR-𝛼 and PPAR-𝛾 were significantly
lower in iPSC-MSCs than BM-MSCs. Also LPL expression
levels were significantly (𝑝 ≤ 0.05) lower in FLF-iPSC-
MSCs (OKSM) and MSC-iPSC-MSCs (OKSM) compared to
BM-MSCs. On the other hand iPSC-MSCs had more affinity
to differentiate to osteogenic and chondrogenic lineages.
Gradually mineral nodules formation started 1 week earlier
in iPSC-MSCs, which were stained positive for alizarin red S.
The expression of osteocalcin and alkaline phosphatase was
comparable to BM-MSCs. Characterizing chondrogenesis,
the respective pellets were stained more strongly with alcian
blue and the respective gene expression profiles for collagen
II showed higher expression in iPSC-MSCs compared to
BM-MSCs. However, Aggrecan was similarly expressed in
all three iPSC-MSCs and BM-MSCs. It has been shown that
someMSCs for instance fromperiosteumand synoviumwere
easily capable of differentiating to bone and cartilage, but
only a minor population amongst them could give rise to
adipocytes [23, 32] and we speculate that such a MSC-related
phenotype is resembled by our iPSC-derived MSCs.
3.3. Supportive Effects on Long-Term CD34+ Cells Mainte-
nance. Thebonemarrowniche plays a vital role in preserving
hematopoietic progenitors to provide proper amounts of
blood cells throughout life [33, 34].This activemicroenviron-
ment is fostered by secreted factors of niche-accompanying
cells such asMSCs and sinusoidal endothelial cells to support



















































































































Figure 4: Adipogenic, osteogenic, and chondrogenic differentiation potential of hiPSC-MSCs and BM-MSC (LM06). Oil Red-O staining for
lipid formation, alizarin red staining of mineralized deposits, and alcian blue staining for chondrocyte pellet formed by the three iPSC-MSC-
like cell lines. mRNA expression level of the relative expression of genes associated with adipogenesis PPAR𝛾, PPAR𝛼, and LPL, osteogenesis
(osteocalcin and alkaline phosphatase), and chondrogenesis (collagen type II and aggrecan). The data represent the mean expression values
normalized to the housekeeping gene GAPDH. ∗: significance difference with BM-MSCs 𝑝 ≤ 0.05.
the quiescent state of some of the hematopoietic progenitors
[35, 36]. The supportive cellular microenvironment provided
by MSCs regulates self-renewal versus differentiation of
hematopoietic stem/progenitor cells within the bone marrow
[37, 38]. Moreover, based on their secretion of cytokines
supportive for hematopoietic cell proliferation, MSC are
considered to serve as an excellent cell type for long-term
progenitor cell culture purposes [39]. As further indication
for the undisturbed functional capabilities of iPSC-MSCs
we exploited a coculture system of iPSC-MSCs and CD34+
hematopoietic stem/progenitor cells and investigated the
total cell numbers, the colony forming capacity, and the
homogeneity of CD34+ cells. After 10 days, all three iPSC-
MSC coculture assays contained significantly (𝑝 ≤ 0.05)















































































































































Figure 5: Coculture of CD34+ PBMCs with human iPSC-MSCs. (a) Cell layers of iPSC-MSCs and BMSCs were established on 1% gelatin
precoated 24-well plates (80% confluent). CD34+ PBSCs were applied onto the stromal layers. The cocultures were incubated for 20
days. Nonadherent viable cells were counted at the indicated time points, (b) human CD34+ were plated with hiPSC-MSCs in 0.5mL of
methylcellulose media containing human recombinant IL-3, SCF, and Epo.The plates were incubated for 20 days following which progenitors
were scored, (c) surface markers expression on CD34+ cells after coculture with mesenchymal stromal cells. The results represent the mean
(±SD) of three replicates. ∗: significance difference with CD34 without stroma 𝑝 ≤ 0.05.
more nonadherent cells compared to CD34+ cells cultured
without any stroma. Comparing coculture of CD34+ cells
with iPSC-MSCs andBM-MSCs, we observed a robust (but in
our experiments not significant) increase in nonadherent cell
numbers for the iPSC-MSCs assays (Figure 5(a)). For OSKM
factors-derived iPSC-MSCs (Figure 5(a)) similar results were
obtained even at day 20. After replating CD34+ cells in
MethoCult media for colony forming assays, we observed
significantly increased colonies in all iPSC-MSCs and BM-
MSCs lines after 4 days of coculture comparing to single
CD34+ culture. Furthermore, MethoCult culture for 8 days
resulted in significantly (𝑝 ≤ 0.05) higher colony numbers
in iPSC-MSCs and in 2 lines of BM-MSCs (Figure 5(b)).
This data demonstrates a further important functional aspect
and is supported by prior investigations that indicated the
supportive nature of MSCs on hematopoiesis by providing
a suitable microenvironment for stem/progenitor cells in
growing sites [40]. With our data we also provided evidence
that significantly higher CD34+ cell number maintain their
stem cell status on the iPSC-MSCs and BM-MSCs rather than
conventional hematopoietic medium (Figure 5(c)). These
enhanced proliferation and boosted colony forming abilities
could be observed after 8 days of coculture in all iPSC-
MSCs lines suggesting that these represent a reliable cell
source supporting the long-term culture of hematopoietic
stem/progenitor cells. Several publications are in favor of the
effects of different feeder layers and coatings for maintenance
and expansion of progenitors and somatic cells showing the
importance of mimicking in vivo conditions and providing
similar microenvironment [41–43].
3.4. Immunosuppressive Effects of iPSC-MSCs. In pioneer-
ing studies mesenchymal stem cell based approaches were
applied for suppressing immune reactions in autoimmune
disorders, graft versus host disease (GVHD), or after solid
organ transplantation (for review see [44, 45]). During
allogeneic cell or organ transplantation, cytotoxic and helper
T-lymphocytes get activated and kill the targeted cells or
promote rejection of the transplanted organ [46]. Because
MSCs can secrete anti-inflammatory molecules to dampen























































































































































Figure 6: Status of activatedCD4+ T cells in the presence of hiPSC-MSCs. (a) IFN-𝛾were determined at 48 hours by ELISA.The values are the
means ± SD from 3 independent experiments, (b) concentrations of IL-2, and (c) proliferation in MLR/MSC cocultures. MLR cultures were
set up in presence or absence of hiPSC-MSCs. BrdU incorporation was significantly lower in MSC-ips-MSCs and FLFiPSC-MSCs (OSNL)
in comparison to absence of MSCs. (d) Expression of the T-cell activation markers CD69 and (e) CD25 on CD4+ 5 days after stimulation in
a 12-well dish in the presence or absence of hiPSC-MSCs. ∗: significance difference with MLR 𝑝 ≤ 0.05.
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inflammatory reaction [47], one can speculate that iPSC-
derived MSCs could also provide a valuable cell source for
immunomodulatory therapies (for review see [11]). In order
to investigate the immunomodulatory properties of iPSC-
MSCs we have used Mixed Lymphocyte Reaction (MLR)
to mimic inflammatory reaction by mixing CD4+ lympho-
cytes with healthy donor peripheral blood mononuclear
cells (PMNCs) on iPSC-MSCs and BM-MSCs feeder layers,
respectively. First, we checked the CD4+ lymphocyte prolif-
eration in MLR assay by BrdU incorporation. Human FLF-
iPSC-MSCs (OSNL) and hMSC-iPSC-MSCs (OSKM) could
significantly (𝑝 ≤ 0.05) dampen lymphocyte proliferation
and we observed a similar decrease in FLF-iPSC-MSCs
(OSKM) and BM-MSCs (Figure 6(a)). MSCs are known to
exhibit regulatory properties on different kinds of immune
cells including T-lymphocytes, but so far it has been insuf-
ficiently considered to what extent iPSC-MSCs display this
modulating activity. Previously, immune regulatory effects of
iPSC-MSCs on Natural Killer (NK) cells have been studied
by Giuliani et al., where it was indicated that the NK-cell
cytolytic machinery was disrupted by inhibiting NK-cell
proliferation and IL-2 activation via expression of different
activation markers and ERK1/2 signaling [48]. There is also
plenty of evidence that lymphocyte can be suppressed by
MSCs secreting anti-inflammatory cytokines in response to
proinflammatory stimuli mediated through IL-2 and IFN-
𝛾 [49, 50]. Therefore we investigated the amount of IFN-
𝛾 (Figure 6(b)) and IL-2 (Figure 6(c)) in the supernatant
of MLR assays from the iPSC-MSC coculture experiments.
While we could observe a significant decrease of IFN-𝛾 levels
in the iPSC-MSC and BM-MSCs coculture experiments,
we could only detect a minor reduction of IL-2 levels in
the control BM-MSC coculture experiment as well as in
the iPSC-MSC experiments. Nevertheless, these results are
supporting previous findings that MSCs can dampen inflam-
matory response via suppressing T-cell proliferation [51] and
decreasing proinflammatory cytokines due to nitric oxide
production that inhibits Stat-5 phosphorylation in memory
and cytotoxic T-cells [4]. Previously it has been reported that
MLR coculture with MSCs significantly increases regulatory
markers (CD69 and CD25) expressing population in CD4+
cells [5, 52–54]. Our results indicated that MSC-iPSC-MSCs
and BM-MSCs significantly increased the early T-cell acti-
vation marker CD69+ population compared to MLR alone
(Figure 6(d)). Even if the increase in CD69+ population in
FLF-iPSC-MSCs did not reach the level of significance, we
speculate that these cells have an immunomodulatory impact
as well. Moreover all iPSC-MSCs as feeder layer have the
ability to significantly increase CD25+ population compared
to MLR alone (Figure 6(e)), which is in line with previous
publications [52, 55].
4. Conclusion
Here, we describe a lentiviral selection cassette mediated
allowing the enrichment of highly functional human iPSC-
derived MSCs from different somatic starting cells. Such
iPSC-MSCs exhibited higher proliferation capabilities and
similar surface marker compared to bona fide MSCs derived
from bone marrow. Moreover, we were able to demonstrate
that iPSC-MSCs support the long-term culture of CD34+
hematopoietic stem/progenitor cells with undisturbed colony
forming abilities. Finally, human iPSC-MSCs also exhib-
ited immunomodulatory function with lowering CD4+ T-
lymphocyte population, decreasing IFN-𝛾 secretion, and
increasing regulatory T-cell population. Thus, iPSC-MSCs
might be considered as relevant cell resource for future
transplantation studies in preclinical models of GVHD and
degenerative autoimmune diseases.
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